External validation of nomograms for prediction of progression-free survival and liver toxicity in patients with advanced renal cell carcinoma treated with pazopanib.
Aged
Angiogenesis Inhibitors
/ adverse effects
Carcinoma, Renal Cell
/ drug therapy
Chemical and Drug Induced Liver Injury
/ etiology
Female
Humans
Indazoles
Kidney Neoplasms
/ drug therapy
Male
Middle Aged
Nomograms
Progression-Free Survival
Pyrimidines
/ adverse effects
Retrospective Studies
Sulfonamides
/ adverse effects
Survival Rate
Japanese
Nomogram
Pazopanib
Renal cell carcinoma
Validation
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
01
11
2018
accepted:
19
01
2019
pubmed:
25
2
2019
medline:
28
7
2019
entrez:
25
2
2019
Statut:
ppublish
Résumé
Nomograms have been developed for the prediction of progression-free survival (PFS) and liver toxicity in patients with advanced renal cell carcinoma (RCC) who are treated with pazopanib. The objectives of this study were to review clinical outcomes, to perform an external validation of these nomograms and to develop a new nomogram in Japanese patients. A retrospective chart review of 150 Japanese patients with advanced RCC who received pazopanib at Kobe University Hospital and affiliated hospitals from March 2014 to June 2017 was performed. We evaluated the clinical efficacy and safety of pazopanib using logistic regression analysis to analyze the prognostic factors for overall survival (OS) and PFS. For nomogram validation, concordance index (C-index) and calibration were used. The median PFS and OS in this study was 13.1 and 37.4 months, respectively. Multivariate analyses identified prognostic factors for OS (number of metastasis, white blood cell (WBC) count and lactate dehydrogenase) and PFS (number of metastasis, WBC count). The C-index of nomograms for 12-month PFS was 0.598. The C-index of nomograms for liver toxicity was 0.558. A new Nomogram for predicting 12-month PFS for patients who received pazopanib was developed and performed internal validation. The C-index of the nomogram was 0.768. The clinical effect and safety of pazopanib reported in this study was similar to previous studies. This study suggests careful application of nomograms to Japanese patients treated with pazopanib. We have developed a new nomogram for predicting 12-month PFS with pazopanib therapy from Japanese patients.
Sections du résumé
BACKGROUND
BACKGROUND
Nomograms have been developed for the prediction of progression-free survival (PFS) and liver toxicity in patients with advanced renal cell carcinoma (RCC) who are treated with pazopanib. The objectives of this study were to review clinical outcomes, to perform an external validation of these nomograms and to develop a new nomogram in Japanese patients.
METHODS
METHODS
A retrospective chart review of 150 Japanese patients with advanced RCC who received pazopanib at Kobe University Hospital and affiliated hospitals from March 2014 to June 2017 was performed. We evaluated the clinical efficacy and safety of pazopanib using logistic regression analysis to analyze the prognostic factors for overall survival (OS) and PFS. For nomogram validation, concordance index (C-index) and calibration were used.
RESULTS
RESULTS
The median PFS and OS in this study was 13.1 and 37.4 months, respectively. Multivariate analyses identified prognostic factors for OS (number of metastasis, white blood cell (WBC) count and lactate dehydrogenase) and PFS (number of metastasis, WBC count). The C-index of nomograms for 12-month PFS was 0.598. The C-index of nomograms for liver toxicity was 0.558. A new Nomogram for predicting 12-month PFS for patients who received pazopanib was developed and performed internal validation. The C-index of the nomogram was 0.768.
CONCLUSION
CONCLUSIONS
The clinical effect and safety of pazopanib reported in this study was similar to previous studies. This study suggests careful application of nomograms to Japanese patients treated with pazopanib. We have developed a new nomogram for predicting 12-month PFS with pazopanib therapy from Japanese patients.
Identifiants
pubmed: 30798395
doi: 10.1007/s10147-019-01401-5
pii: 10.1007/s10147-019-01401-5
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Indazoles
0
Pyrimidines
0
Sulfonamides
0
pazopanib
7RN5DR86CK
Types de publication
Journal Article
Validation Study
Langues
eng
Pagination
698-705Références
J Urol. 2000 Feb;163(2):408-17
pubmed: 10647643
J Clin Oncol. 2002 Jan 1;20(1):289-96
pubmed: 11773181
Ann Oncol. 2002 Sep;13(9):1460-8
pubmed: 12196373
Cancer. 2007 Aug 1;110(3):543-50
pubmed: 17577222
Cancer. 2008 Jul 1;113(1):78-83
pubmed: 18491376
Cancer. 2008 Oct 1;113(7):1552-8
pubmed: 18720362
J Clin Oncol. 2009 Dec 1;27(34):5794-9
pubmed: 19826129
J Clin Oncol. 2010 Feb 20;28(6):1061-8
pubmed: 20100962
Jpn J Clin Oncol. 2010 Oct;40(10):980-5
pubmed: 20457723
Jpn J Clin Oncol. 2010 Dec;40(12):1166-72
pubmed: 20713418
Clin Cancer Res. 2011 Aug 15;17(16):5443-50
pubmed: 21828239
Asia Pac J Clin Oncol. 2014 Sep;10(3):237-45
pubmed: 24576311
N Engl J Med. 2014 May 1;370(18):1769-70
pubmed: 24785224
Eur J Cancer. 2015 Jul;51(10):1293-302
pubmed: 25899987
Oncology. 2015;89(4):235-41
pubmed: 26088013
Target Oncol. 2017 Aug;12(4):543-554
pubmed: 28664385
Crit Rev Oncol Hematol. 2018 Jan;121:45-50
pubmed: 29279098
Scand J Urol Nephrol. 1987;21(4):285-9
pubmed: 3445125